The U.S. cannabis stocks we’ve discovered have IPO’d/RTO’d in Canada during the past three months and are trading below their initial listing price
SmallCapPower | December 24, 2018: On Friday, we identified 3 U.S. cannabis stocks that have outperformed since their IPO/RTO. Today, we have weeded out three such cannabis companies that have seen a sharp decline in their share price and are now trading at a discount to their initial listing. Scotiabank estimates the American cannabis market to be worth upwards of 65B per year, making these companies interesting targets to monitor should a rebound occur.
To see the top-performing listings mentioned from Friday’s article please click here
*Share prices are as at close 21-Dec-2018.
MJardin Group Inc. (CSE: MJAR) – $2.89
MJardin Group offers its partners cannabis cultivation, processing, and retail solutions. Their services include: licensure support, facility design, systems implementation, equipment leasing and facility ramp-up services, as well as day-to-day personnel management. The Company has 34 cultivation, processing, and retail facilities across the U.S. and Canada. MJardin has 10 years of “seed-to-sale” experience and 465,000 sq. in operation/under development and a 55,000 kg production capacity per year.
Acreage Holdings Inc. (CSE: ACRG.U) – $13.35
Acreage Holdings is a multi-state owner of cannabis licenses and assets in the U.S. and has operating licenses in 18 states. The Company takes minority interests in cannabis companies and has the option to roll-up the investments to gain majority ownership. Acreage is dedicated to building and scaling operations to create a seamless, consumer-focused branded cannabis experience.
- Market Cap: US$274.5 million
- Listing Date: November 15, 2018
- Listing Price: $25.00
- % Change: – 46.6%
Dixie Brands Inc. (CSE: DIXI.U) – $0.41
Dixie Brands designs, manufactures, and distributes marijuana-infused products. DBI focuses on segments of the value chain that include extraction, product development, manufacturing, branding and distribution and avoids the more capital-intensive segments, such as cultivation and retailing. The Company has over 100 products across more than 15 different product categories, representing the industry’s finest edibles, tinctures, topicals and connoisseur-grade extractions, as well as world-class CBD-infused wellness products (relaxation, immunity development, and pain management) and pet dietary supplements.
Disclosure: Neither the author nor his family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below: